EP0302862A1 - Behandlung von krebs mit gamma-interferon - Google Patents

Behandlung von krebs mit gamma-interferon

Info

Publication number
EP0302862A1
EP0302862A1 EP87902004A EP87902004A EP0302862A1 EP 0302862 A1 EP0302862 A1 EP 0302862A1 EP 87902004 A EP87902004 A EP 87902004A EP 87902004 A EP87902004 A EP 87902004A EP 0302862 A1 EP0302862 A1 EP 0302862A1
Authority
EP
European Patent Office
Prior art keywords
human
gamma interferon
human gamma
treatment
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP87902004A
Other languages
English (en)
French (fr)
Inventor
Paul Philip Trotta
Tattanahali L. Nagabhushan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of EP0302862A1 publication Critical patent/EP0302862A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • Gamma interferon has a number of charac ⁇ teristics known in the art that differentiate it from alpha and beta interferons. Among these differences are antigenic distinctiveness and higher levels of immunoregulatory and an i umor activity. Human gamma interferon may be produced by T-lymphocytes stimulated by mitogens or by antigens to which they are sensitized. It may also be obtained through cloning and expression techniques now well known in the art.
  • hlFN- ⁇ is of a high purity material that is not contaminated by cell constitutents or cell debris of the interferon-expressing cell.
  • a preferred hlFN- ⁇ used in this invention is produced by recombinant DNA technology and then purified as taught in Japanese Patent Application No. 59-281376, filed December 12,1984 and foreign counterparts thereof, e.g. the European Patent Application, all of which are incorporated by reference herein.
  • the purification process comprises adding one or more salts of 2inc or copper and polyethyleneimine in the extraction.
  • it comprises suspending the culture cells of a recombinant microorganism in a buffer solution containing one or more salts of zinc or copper, e.g. zinc chloride, zinc sulfate, zinc acetate, zinc acetylacetonate and copper sulfate, in a range of about 0.5 - 5mM in the case of zinc salts and 0.01 - 3mM in the case of copper salts, disrupting the cells, then adding polyethyleneimine to the centrifuged supernatant, e.g. to a final concentration of 0.5 - 1.1%, and subsequently purifying by a conventional method, e.g. combining several chromatographi ⁇ methods and dialysis.
  • a buffer solution containing one or more salts of zinc or copper, e.g. zinc chloride, zinc sulfate, zinc acetate, zinc acetylacetonate and copper sulfate, in a range of about 0.5 - 5mM in the case of zinc
  • Human gamma interferon can be made, for example, by the procedures disclosed in Gray et al, Nature, 295, 503-508 (1982) and Epstein, Nature, 295, 453-454 (1982).
  • This invention relates to a method of treating human ovarian, breast, lung, melanoma, kidney, pancreatic, cervical, colon, brain, pleural and stomach cancers by administering to a patient in need of such treatment a sufficient amount of purified human gamma interferon to be effective an an antitumor agent.
  • the preferred mode of administration is parenteral, i.e. intravenous, intramuscular, subcutaneous and in raperitoneal.
  • ovarian 3/9 10 100 and 1,000 lung (non-small cell) 1/11 100 and 1,000 lung (unknown) 1/1 100 and 1,000 melanoma 1/6 1,000 kidney 1/1 1,000 pancreatic 1/2 1,000 cervical 1/1 100 and 1,000 colon 1/4 1,000 brain 1/1 1,000 pleural 1/2 100 stomach 1/3
  • Table I shows that human gamma interferon has antitumor activity against the cancers listed.
  • lung non-small cell 1/3 10 ovarian 2/3 100 and 1,000 pancreatic 1/1 1,000
  • hlFN- ⁇ administered as well as the regimen and form of administration is dependent on the judgement of the clinician, taking into account a variety of factors including the patient's tumor's response to hlFN- ⁇ .
  • Human gamma interferon is preferably administered parenterally, e.g. intravenously (IV), intramuscularly (IM) , subcutaneously (SO or intraperitoneally (IP), in conventional dosage forms, i.e. sterile aqueous solutions or suspensions.
  • parenterally e.g. intravenously (IV), intramuscularly (IM) , subcutaneously (SO or intraperitoneally (IP), in conventional dosage forms, i.e. sterile aqueous solutions or suspensions.
  • the formulations for these conventional dosage forms include the active compound and conventional pharmaceutically acceptable carriers, adjuvants, fillers, binders, disintegrants and the like.
  • the hlFN- ⁇ will be parenterally administered, on a per day basis, in the range of about 0.1 mg to 10 mg and preferably from about 0.1 mg to 10 mg in divided doses.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP87902004A 1986-03-17 1987-03-13 Behandlung von krebs mit gamma-interferon Withdrawn EP0302862A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84030286A 1986-03-17 1986-03-17
US840302 1986-03-17

Publications (1)

Publication Number Publication Date
EP0302862A1 true EP0302862A1 (de) 1989-02-15

Family

ID=25281977

Family Applications (1)

Application Number Title Priority Date Filing Date
EP87902004A Withdrawn EP0302862A1 (de) 1986-03-17 1987-03-13 Behandlung von krebs mit gamma-interferon

Country Status (3)

Country Link
EP (1) EP0302862A1 (de)
JP (1) JPH01501792A (de)
WO (1) WO1987005518A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11499028B2 (en) * 2017-08-04 2022-11-15 Basf Se Expandable, expanding-agent-containing granules based on high-temperature thermoplastics

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0278715A3 (de) * 1987-02-09 1989-03-08 Schering Corporation Verwendung von menschlichem Gamma-Interferon für die Behandlung von Basalzell-Karzinomen
US5268169A (en) * 1989-02-02 1993-12-07 Roussel Uclaf Treatment method of ovarian cancer using interferon gamma
FR2644067B1 (fr) * 1989-02-02 1993-02-05 Roussel Uclaf Utilisation de certains interferons gamma pour la preparation de compositions pharmaceutiques destinees au traitement du cancer de l'ovaire par voie intraperitoneale
FR2654343B1 (fr) * 1989-11-10 1994-08-05 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interferon gamma pour la preparation de compositions pharmaceutiques destinees au traitement de cancers primitifs de la plevre.
JP4523762B2 (ja) * 2003-06-11 2010-08-11 学校法人日本大学 腫瘤形成抑制方法
EP2298862B1 (de) 2004-03-22 2017-08-30 Mesoblast International Sàrl Mesenchymale Stammzellen und deren Verwendungen
TR201901268T4 (tr) * 2004-03-22 2019-02-21 Mesoblast Int Sarl Mezenkimal kök hücreleri ve bunların kullanımları.
CN114010791B (zh) * 2021-11-15 2023-11-24 济南市中心医院 MyD88-IFNγR1二聚体作为靶点在制备预防结肠癌的药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983001198A1 (en) * 1981-10-08 1983-04-14 Kurt Frimann Berg Method and composition for treating a patient suffering from interferon-susceptible disorder
EP0088540A3 (de) * 1982-02-22 1984-10-17 Biogen, Inc. DNS-Sequenzen, Rekombinante DNS-Moleküle und Verfahren zur Herstellung von dem immunen menschlichen Interferon ähnlichen Polypeptiden
ZA83768B (en) * 1982-03-01 1983-10-26 Hoffmann La Roche Homogeneous human immune interferon and process therefor
JPS6087300A (ja) * 1983-10-18 1985-05-16 Green Cross Corp:The インタ−フエロン−γ組成物
GB8328820D0 (en) * 1983-10-28 1983-11-30 Searle & Co Synthetic human gamma interferon gene
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
ATE66375T1 (de) * 1984-10-05 1991-09-15 Bioferon Biochem Substanz Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von verschiedenen erkrankungen des menschen in niedriger dosierung.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8705518A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11499028B2 (en) * 2017-08-04 2022-11-15 Basf Se Expandable, expanding-agent-containing granules based on high-temperature thermoplastics

Also Published As

Publication number Publication date
WO1987005518A1 (en) 1987-09-24
JPH01501792A (ja) 1989-06-22

Similar Documents

Publication Publication Date Title
Armitage et al. Effect of Chemotherapy for the Dysmyelopoietic Syndrome 1, 2
Blomgren et al. Interferon therapy in Hodgkin's disease: a case report
Cheema et al. Patient survival after chemotherapy and its relationship to in vitro lymphocyte blastogenesis
JP2813017B2 (ja) 癌療法の副作用の減少方法
Einhorn et al. Human leukocyte interferon therapy for advanced ovarian carcinoma
Gahrton et al. Involvement of chromosomes 8, 9, 19 and 22 in Ph1 positive and Ph1 negative chronic myelocytic leukemia in the chronic or blastic stage
EP0302862A1 (de) Behandlung von krebs mit gamma-interferon
Sato et al. Enhancement by interferon of natural cytotoxic activities of lymphocytes from human cord blood and peripheral blood of aged persons
Piccolo et al. Myasthenia gravis in a patient with chronic active hepatitis C during interferon-alpha treatment.
Ito et al. Effect of human leukocyte interferon on the metastatic lung tumor of osteosarcoma. Case reports
Taguchi Clinical studies of recombinant interferon alfa‐2a (Roferon®‐A) in cancer patients
Ortaldo et al. Protective effects of interferon in mice previously exposed to lethal irradiation
GARSON et al. The 45, XO, Ph 1 subgroup of chronic granulocytic leukaemia
JPS63501013A (ja) アレルギ−の処置方法
Fenichel et al. Immunomodulating and Antimetastatic Activity of 3–(P-Chlorophenyl) Thiazolo [3, 2-A] Benzimidazole-2-Acetic Acid (Wy-18, 251, Nsc 310633)
US5190751A (en) Treatment of certain leukemias with a combination of gamma interferon and alpha interferon
EP0276120B1 (de) Behandlung von einigen Leukämien mit einer Zusammensetzung von Interferon-gamma und Interferon-alpha
Hall et al. Infective endocarditis following human-to-human enterococcal transmission: a complication of intravenous narcotic abuse
Fefer et al. Leukaemia antigens. Stimulation of lymphocytes in mixed culture by cells from HL-A identical siblings
Swain et al. Rosette Formation in Hodgkin’s Disease: Effect of Treatment
JPS60501558A (ja) インタ−フエロン感受性疾病の治療方法およびγ−インタ−フエロン含有製剤の製造方法および装置
Hokland et al. Effect of recombinant alpha interferon on NK and ADCC function in lung cancer patients: results from a phase II trial
CN116036281A (zh) 钠-葡萄糖协同转运蛋白2抑制剂在制备肿瘤免疫治疗药物中的应用
EP0384498B1 (de) Pharmazeutische Verbindung für die Induktion der Produktion von Cytokinen
Bryan et al. The effect of autologous serum on lymphocyte response to human leukemia cells

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19880831

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19900212

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19900823

RIN1 Information on inventor provided before grant (corrected)

Inventor name: NAGABHUSHAN, TATTANAHALI, L.

Inventor name: TROTTA, PAUL, PHILIP